Description:

ODM derived from http://clinicaltrials.gov/show/NCT00404092

Link:

http://clinicaltrials.gov/show/NCT00404092

Keywords:
Versions (1) ▾
  1. 12/9/13
Uploaded on:

December 9, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00404092 Invasive Aspergillosis

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 18 Years
Immunocompromised due to hematologic malignancies, bone marrow failure syndromes, hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, HIV infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections.
Evidence of proven or probable invasive aspergillosis, by modified EORTC criteria
Exclusion Criteria
Concomitant other systemic antifungal agents are not permitted on study.
Chronic invasive fungal infection, defined as signs/symptoms of invasive fungal infection present for > 4 weeks preceding entry into study
Prior systemic therapy of >= 4 days with any polyene anti-fungal agent within 14 days of study enrollment
Prior systemic therapy of >= 4 days with non-polyenes for the current, documented IFI.